JP2010516708A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516708A5
JP2010516708A5 JP2009546582A JP2009546582A JP2010516708A5 JP 2010516708 A5 JP2010516708 A5 JP 2010516708A5 JP 2009546582 A JP2009546582 A JP 2009546582A JP 2009546582 A JP2009546582 A JP 2009546582A JP 2010516708 A5 JP2010516708 A5 JP 2010516708A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009546582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516708A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/051734 external-priority patent/WO2008091911A2/en
Publication of JP2010516708A publication Critical patent/JP2010516708A/ja
Publication of JP2010516708A5 publication Critical patent/JP2010516708A5/ja
Pending legal-status Critical Current

Links

JP2009546582A 2007-01-22 2008-01-22 抗体結合体の使用 Pending JP2010516708A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89701207P 2007-01-22 2007-01-22
PCT/US2008/051734 WO2008091911A2 (en) 2007-01-22 2008-01-22 Use of antibody conjugates

Publications (2)

Publication Number Publication Date
JP2010516708A JP2010516708A (ja) 2010-05-20
JP2010516708A5 true JP2010516708A5 (enExample) 2012-03-01

Family

ID=39645132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009546582A Pending JP2010516708A (ja) 2007-01-22 2008-01-22 抗体結合体の使用

Country Status (6)

Country Link
US (2) US20100143358A1 (enExample)
EP (1) EP2109625A4 (enExample)
JP (1) JP2010516708A (enExample)
AU (1) AU2008207948A1 (enExample)
CA (1) CA2676234A1 (enExample)
WO (1) WO2008091911A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
US8609615B2 (en) 2008-10-15 2013-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of myotonic dystrophy
CA2799608C (en) * 2009-05-28 2023-02-28 Richard H. Weisbart Amino acid sequences which enhance peptide conjugate solubility
AU2010260145B2 (en) 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
WO2012135831A1 (en) * 2011-04-01 2012-10-04 Yale University Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair
EP2694112B1 (en) * 2011-04-07 2017-11-08 Memorial Sloan-Kettering Cancer Center Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer
WO2013138662A1 (en) 2012-03-16 2013-09-19 4S3 Bioscience, Inc. Antisense conjugates for decreasing expression of dmpk
US9283272B2 (en) * 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US12195550B2 (en) 2012-03-30 2025-01-14 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
WO2013177428A1 (en) * 2012-05-23 2013-11-28 Valerion Therapeutics, Inc. Methods for increasing muscle contractility
US10017581B2 (en) 2013-02-20 2018-07-10 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
AU2015204446A1 (en) 2014-01-13 2016-07-14 Valerion Therapeutics, Llc Internalizing moieties
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
EP3186278A4 (en) 2014-08-27 2018-04-04 Valerion Therapeutics, LLC Internalizing moieties for treatment of cancer
US10709761B2 (en) 2015-10-08 2020-07-14 University Of Utah Research Foundation Methods and compositions for preventing or treating cancer
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
AU2017286733B2 (en) 2016-06-15 2020-07-02 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
US12304970B2 (en) 2018-02-01 2025-05-20 Yale University Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
CN112236162A (zh) 2018-04-06 2021-01-15 昂科莱奇公司 用于裂解选择性癌细胞的组合物
US12103968B2 (en) 2018-08-16 2024-10-01 The Johns Hopkins University Antibodies to human ZnT8
KR20210053930A (ko) 2018-08-31 2021-05-12 예일 유니버시티 공여자 올리고뉴클레오티드 기반의 유전자 편집을 향상시키기 위한 조성물 및 방법
AU2020336992A1 (en) 2019-08-30 2022-04-14 Yale University Compositions and methods for delivery of nucleic acids to cells
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
EP4387666A4 (en) * 2021-08-20 2025-07-16 Univ Johns Hopkins CELL SURFACE ANTIBODY FOR A PANCREATIC BETA CELL SPECIFIC BIOMARKER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812397A (en) * 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
JP2000507225A (ja) * 1996-03-08 2000-06-13 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア mab 3E10 ならびにその突然変異体および/または機能性フラグメントを使用する送達システム
US6485977B1 (en) * 1999-09-13 2002-11-26 Cornell Research Foundation, Inc. Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems

Similar Documents

Publication Publication Date Title
JP2010516708A5 (enExample)
JP2021106617A5 (enExample)
ME02371B (me) Sastojci i postupci za dijagnstikovanje i tretman raka
CA2747064C (en) Monoclonal antibodies directed against lg4/5 domain of alpha3 chain of human laminin-5
RU2018114904A (ru) Антитело против garp
JP2016533721A5 (enExample)
JP2014158469A5 (enExample)
RU2009149205A (ru) Моноклональные антитела против клаудина-18 для лечения рака
RU2009120052A (ru) Композиции и способы связывания сфингозин-1-фосфата
RU2013152164A (ru) Анти-в7-н3-антитело
SI2342234T1 (en) MONOCOLIC ANTI-GT468 CANCER CANCER PROTITEL
RU2013104830A (ru) Лечение рака при помощи направленных на мишень антител in vivo
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
HRP20160584T1 (hr) Novo anti-dr5 antitijelo
JP2010509931A5 (enExample)
JP2019205480A5 (enExample)
JP2013534515A5 (ja) 受容体型チロシンキナーゼc−Metに対する抗体
JP2019513410A5 (enExample)
TW201713700A (zh) 抗glypican-3抗體及其用於診斷及治療癌症之用途
CN115916839A (zh) 抗pdl1×egfr的双特异性抗体
CN115605513A (zh) 一种抗pd-l1和her2的双特异性抗体
JP2018529661A5 (enExample)
JP2007526891A5 (enExample)
JP2018513141A5 (enExample)
KR20250060232A (ko) 항-모노메틸 아우리스타틴 항체 및 항체 단편